TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23093232

Group type: EXPERIMENTAL
Intervention: Transnasal endoscope-assisted ESD
Number of subjects: 51

Group type: COMPARATOR
Intervention: Routine ESD
Number of subjects: 51
Study: 20697028

Group type: EXPERIMENTAL
Intervention: Birth weight category <2.5 kg
Number of subjects: 27982

Group type: EXPERIMENTAL
Intervention: Birth weight category 2.5 to 3.2 kg
Number of subjects: 27982

Group type: EXPERIMENTAL
Intervention: Birth weight category 3.2 to 3.9 kg
Number of subjects: 27982

Group type: EXPERIMENTAL
Intervention: Birth weight category 3.9 to 4.5 kg
Number of subjects: 27982

Group type: EXPERIMENTAL
Intervention: Birth weight category >4.5 kg
Number of subjects: 27982
Study: 19808418

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: PVI plus left linear lesions (LL)
Number of subjects: 204

Group type: COMPARATOR
Intervention: PVI
Number of subjects: 204

Group type: COMPARATOR
Intervention: PVI plus LL
Number of subjects: 204
Study: 16600933

Group type: EXPERIMENTAL
Intervention: HGI-Lac meal (amylopectin starch plus the fermentable disaccharide lactulose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LGI meal (slowly digestible, partly fermentable amylose starch plus cellulose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: HGI meal (amylopectin starch plus cellulose)
Number of subjects: 10
Study: 14584770

Group type: EXPERIMENTAL
Intervention: Nitrofuroxone-impregnated urinary catheters (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Regular silicone-coated Foley catheters (Group B)
Number of subjects: 100
Study: 10758949

Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Number of subjects: 392

Group type: COMPARATOR
Intervention: Coronary bypass surgery
Number of subjects: 392
Study: 8918410

Group type: EXPERIMENTAL
Intervention: Bicalutamide (50 mg once daily) plus LHRH analogue therapy (goserelin acetate 3.6 mg every 28 days or leuprolide acetate 7.5 mg every 28 days)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Flutamide (250 mg three times daily) plus LHRH analogue therapy (goserelin acetate 3.6 mg every 28 days or leuprolide acetate 7.5 mg every 28 days)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Bicalutamide plus LHRH‐A
Number of subjects: 813

Group type: COMPARATOR
Intervention: Flutamide plus LHRH‐A
Number of subjects: 813
Study: 2012293

Group type: EXPERIMENTAL
Intervention: Rectal indomethacin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 6211327

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (0.16 mg by pressurized inhaler; 1 mg nebulized)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salbutamol (0.8 mg by pressurized inhaler; 5 mg nebulized)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ipratropium bromide and Salbutamol
Number of subjects: 8
Study: 31666284

Group type: EXPERIMENTAL
Intervention: Website plus telephonic patient navigation (PN) intervention
Number of subjects: 1043

Group type: COMPARATOR
Intervention: Website intervention
Number of subjects: 1043
Study: 30393868

Group type: EXPERIMENTAL
Intervention: Low-Intensity Pulsed Ultrasound (LIPUS) therapy applied bilaterally for 20 minutes daily for the first 10 days and thereafter at least 3 times per week until complete mandibular advancement was achieved.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no LIPUS therapy).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both test and control groups.
Number of subjects: 40
Study: 28931164

Group type: EXPERIMENTAL
Intervention: Brief face-to-face patient education (3-min one-on-one verbal education by medical students and a pamphlet)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Control group (no verbal health education or pamphlet)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Intervention group (brief face-to-face patient education)
Number of subjects: 529
Study: 26073011

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine
Number of subjects: 47000
Study: 24919569

Group type: EXPERIMENTAL
Intervention: Panitumumab + Rilotumumab
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Panitumumab + Ganitumab
Number of subjects: 142

Group type: COMPARATOR
Intervention: Panitumumab + Placebo
Number of subjects: 142
Study: 23236345

Group type: EXPERIMENTAL
Intervention: Weekly standardized motivational text message
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 19535548

Group type: EXPERIMENTAL
Intervention: Short telomeres on chromosome 9p
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quartile analysis of 9p telomere length
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 18158078

Group type: EXPERIMENTAL
Intervention: BIAsp 30 TID
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: BIAsp 30 BID + MET
Number of subjects: 308

Group type: COMPARATOR
Intervention: OADs
Number of subjects: 308
Study: 15368046

Group type: EXPERIMENTAL
Intervention: Testosterone substitution
Number of subjects: 61
Study: 11394244

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (300 mg alpha‐tocopherol daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oestradiol concentrations (high in preovulatory phase)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation and/or cycle-phase related changes in oestradiol concentrations
Number of subjects: 18
Study: 9608882

Group type: EXPERIMENTAL
Intervention: Fast Melting Tablet (FMT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sugar Coated Tablets (SCT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 18
Study: 8015023

Group type: EXPERIMENTAL
Intervention: 10 micrograms of recombinant yeast‐derived HBV vaccine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 20 micrograms of recombinant yeast‐derived HBV vaccine
Number of subjects: 180
Study: 3050522

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg twice daily)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Heparin (1000 units per hour by intravenous infusion)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Aspirin plus Heparin
Number of subjects: 479

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 479
Study: 30704577

Group type: EXPERIMENTAL
Intervention: iFR
Number of subjects: 872

Group type: COMPARATOR
Intervention: FFR
Number of subjects: 872
Study: 28574158

Group type: EXPERIMENTAL
Intervention: Whitening microneedle patch
Number of subjects: 34

Group type: COMPARATOR
Intervention: Whitening essence
Number of subjects: 34
Study: 26628861

Group type: EXPERIMENTAL
Intervention: Grateziano (400 mg daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Gratisovir (400 mg daily)
Number of subjects: 25
Study: 23337088

Group type: EXPERIMENTAL
Intervention: Active practice receiving regular feedback on film quality
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control practice receiving no feedback
Number of subjects: 40
Study: 21615854

Group type: EXPERIMENTAL
Intervention: Docetaxel and estramustine
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Docetaxel-based chemotherapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Baseline quality of life
Number of subjects: 59
Study: 18289446

Group type: EXPERIMENTAL
Intervention: Intraoperative intravenous tramadol 2 mg kg(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (30 mL saline)
Number of subjects: 60
Study: 16494982

Group type: EXPERIMENTAL
Intervention: Ground linseeds (20 g/d) for 2 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (dietary advice only)
Number of subjects: 40
Study: 12559660

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (600 micro g for 8 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (matching placebo for 8 weeks)
Number of subjects: 15
Study: 11038077

Group type: EXPERIMENTAL
Intervention: rhuMAb CD18 (2 mg/kg)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: rhuMAb CD18 (1 mg/kg)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: rhuMAb CD18 (0.5 mg/kg)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: rhuMAb CD18
Number of subjects: 116
Study: 9075510

Group type: EXPERIMENTAL
Intervention: Painstop (paracetamol 12 mg, codeine 0.5 mg, promethazine 0.65 mg per 1.0 ml, dosage 1.0 ml/kg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Paracetamol 20 mg/kg
Number of subjects: 95
Study: 8369940

Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Immediate appendicectomy
Number of subjects: 60
Study: 3775139

Group type: EXPERIMENTAL
Intervention: Diabetes Teaching Programme (DTP) based on problem oriented participatory education (POPE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional classroom teaching (Control)
Number of subjects: 0
Study: 29266485

Group type: EXPERIMENTAL
Intervention: One-stage ridge augmentation with resorbable membrane (M+)
Number of subjects: 52

Group type: COMPARATOR
Intervention: One-stage ridge augmentation without resorbable membrane (M-)
Number of subjects: 52
Study: 26465791

Group type: COMPARATOR
Intervention: F130
Number of subjects: 0

Group type: COMPARATOR
Intervention: F0
Number of subjects: 0

Group type: COMPARATOR
Intervention: F65
Number of subjects: 0
Study: 23903361

Group type: COMPARATOR
Intervention: Aortic propagation velocity (APV) in ESRD patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pulse wave velocity (PWV) in ESRD patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Carotid intima-media thickness (CIMT) in ESRD patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Correlations between APV and CIMT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Correlations between APV and PWV
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Correlations between PWV and CIMT
Number of subjects: 50
Study: 22246619

Group type: EXPERIMENTAL
Intervention: 400‐mg EGCG as PPE
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 800‐mg EGCG as PPE
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 20163376

Group type: EXPERIMENTAL
Intervention: PF-03491390 (5, 25 or 50 mg) orally twice daily for up to 12 weeks
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 17905607

Group type: EXPERIMENTAL
Intervention: Resilon after retreatment (no further treatment)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Resilon after retreatment (reinstrumented to apical size 60 using K‐files)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Resilon after retreatment (reinstrumented to apical size 60 using ProFile)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (2 roots served as controls)
Number of subjects: 66
Study: 16224143

Group type: EXPERIMENTAL
Intervention: Epicardial microwave ablation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cryosurgical Maze
Number of subjects: 14
Study: 12108617

Group type: EXPERIMENTAL
Intervention: Synthetic human secretin (single dose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10459700

Group type: EXPERIMENTAL
Intervention: 10 mg melatonin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 10158388

Group type: EXPERIMENTAL
Intervention: Site-specific thrombolysis using urokinase with Dispatch catheter
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Site-specific thrombolysis using urokinase with hydrogel-coated balloon
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard techniques for treating intracoronary thrombus
Number of subjects: 68
Study: 2136991

Group type: EXPERIMENTAL
Intervention: Low-energy gallium-arsenide laser treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo laser treatment
Number of subjects: 20
Study: 1115365

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Halothane anesthesia
Number of subjects: 28

Group type: COMPARATOR
Intervention: Chloral hydrate premedication
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pentobarbital and meperidine
Number of subjects: 28
Study: 31773372

Group type: EXPERIMENTAL
Intervention: Laser application with an 810-nm GaAlAs laser device at 0, 3, 7, 14, 21, and 28 days to 8 J/cm2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LED application with an 850-nm wavelength and 20 mW/cm2 output power for 10 min per day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo therapy with a laser device that did not make active pulses
Number of subjects: 30
Study: 29369843

Group type: EXPERIMENTAL
Intervention: Smartwatch feedback application
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 30
Study: 29178842

Group type: EXPERIMENTAL
Intervention: Fixed combination of pepsin and amino acid hydrochloride taken as tablets three times daily for 6 weeks
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Fixed combination of pepsin and amino acid hydrochloride
Number of subjects: 97
Study: 26571905

Group type: EXPERIMENTAL
Intervention: PBL and LEL
Number of subjects: 2010

Group type: COMPARATOR
Intervention: LBL
Number of subjects: 2010
Study: 23681296

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) at stimulus intensity ranging from 40 to 100% stimulator output in intervals of 10%.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Plantar flexors at knee angle of 180° (PF180).
Number of subjects: 7

Group type: COMPARATOR
Intervention: Plantar flexors at knee angle of 90° (PF90).
Number of subjects: 7
Study: 21270385

Group type: EXPERIMENTAL
Intervention: Permissive underfeeding
Number of subjects: 100

Group type: COMPARATOR
Intervention: Target feeding
Number of subjects: 100
Study: 18593092

Group type: EXPERIMENTAL
Intervention: Evidence-based resources for dentists (e.g., journals, online resources like PubMed and Cochrane Collaboration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research methodologies in evidence-based dentistry
Number of subjects: 0
Study: 17201610

Group type: EXPERIMENTAL
Intervention: Quetiapine (400-600 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Divalproex (serum level 80-120 microg/mL)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Comparison of both treatments
Number of subjects: 33
Study: 12749423

Group type: EXPERIMENTAL
Intervention: Fixed group (GnRH antagonist starting on day 6 of stimulation)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Flexible group (GnRH antagonist starting when a follicle of > or = 15 mm was present)
Number of subjects: 111
Study: 10878693

Group type: EXPERIMENTAL
Intervention: Health Centre
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hospital
Number of subjects: 50
Study: 8813484

Group type: EXPERIMENTAL
Intervention: Octreotide (3 X 100 micrograms/day subcutaneously)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 1350491

Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Propranolol (40 mg)
Number of subjects: 16
Study: 6465819

Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chest physiotherapy with bronchodilatation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chest physiotherapy without bronchodilatation
Number of subjects: 0
Study: 31689808

Group type: EXPERIMENTAL
Intervention: Kyung-Ok-Ko
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29910054

Group type: EXPERIMENTAL
Intervention: Adaptive servoventilation (ASV) + Optimal Medical Therapy (OMT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT) alone
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Adaptive servoventilation (ASV)
Number of subjects: 126
Study: 26079867

Group type: EXPERIMENTAL
Intervention: 15-minute exercise session focused on hand training using therapeutic putty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active upper limb exercises (Control)
Number of subjects: 60
Study: 24075564

Group type: COMPARATOR
Intervention: Modified Blalock‐Taussig shunt
Number of subjects: 393

Group type: COMPARATOR
Intervention: Right ventricle‐to‐pulmonary artery shunt
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Nonelective timing of the stage 2 procedure
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Pulmonary artery (PA) stenosis
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Moderate or greater atrioventricular valve (AVV) regurgitation
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: AVV repair
Number of subjects: 393
Study: 22356661

Group type: EXPERIMENTAL
Intervention: Education by a dentist
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Peer-teaching
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Adherence triangle concept (dentists, teachers, participants)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control (approaches I and II)
Number of subjects: 157
Study: 20456213

Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil orodispersible tablet (ODT)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study: 16221751

Group type: EXPERIMENTAL
Intervention: Motor sequence learning task (30 minutes)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonrepetitive sequence movements (30 minutes)
Number of subjects: 30
Study: 12814931

Group type: EXPERIMENTAL
Intervention: Radioisotope localization (ROLL)
Number of subjects: 38
Study: 10617943

Group type: EXPERIMENTAL
Intervention: Encapsulated fish oil (1.45 g eicosapentaenoic acid and 1.55 g docosahexaenoic acid/d) for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (11 normolipidemic subjects)
Number of subjects: 14
Study: 9382759

Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (age and gender-matched)
Number of subjects: 26
Study: 1554923

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg/d during five months
Number of subjects: 199
Study: 3754234

Group type: EXPERIMENTAL
Intervention: piperazinedione 9 mg/m2 iv every 3 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: cisplatin 50 mg/m2 iv every 3 weeks
Number of subjects: 37
Study: 30816148

Group type: EXPERIMENTAL
Intervention: 500 mg of a combination of polyphenolic extracts from Lippia citriodora L. and Hibiscus sabdariffa L. (LC-HS)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 29384083

Group type: EXPERIMENTAL
Intervention: sANSWERS method combining VF and OCT data
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ANSWERS method
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: PoPLR method
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: GPA method
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: sANSWERS method
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: PERM method
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: MaHMIC and MaGIC analyses
Number of subjects: 72
Study: 27867308

Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 25238909

Group type: COMPARATOR
Intervention: Leucovorin 0 mg/m2
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Leucovorin 60 mg/m2
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Leucovorin 200 mg/m2
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Leucovorin 500 mg/m2
Number of subjects: 80
Study: 22729297

Group type: EXPERIMENTAL
Intervention: Dexamethasone (6 mg/ml)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo (saline 1 ml)
Number of subjects: 185
Study: 20164321

Group type: EXPERIMENTAL
Intervention: Maltodextrin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Whole-grain cornstarch
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High-amylose cornstarch
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Regular cornstarch
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: All starch treatments
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 5
Study: 17673380

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo crossover to Infliximab
Number of subjects: 378
Study: 16574937

Group type: EXPERIMENTAL
Intervention: 1018 ISS (36 mg by nebulization weekly for 4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14606080

Group type: EXPERIMENTAL
Intervention: Capsule oxymatrine
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Injection of oxymatrine
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 11023565

Group type: EXPERIMENTAL
Intervention: 7F double‐pigtail stent placement for 6 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Long-term stent placement
Number of subjects: 20
Study: 8881618

Group type: EXPERIMENTAL
Intervention: Alfentanil 1 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lignocaine 40 mg
Number of subjects: 66
Study: 1544695

Group type: EXPERIMENTAL
Intervention: Tamoxifen (30 mg daily)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 3979476

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum
Number of subjects: 32

Group type: COMPARATOR
Intervention: Tetracycline hydrochloride (intercostal needle)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Tetracycline hydrochloride (intercostal tube)
Number of subjects: 32
Study: 31074689

Group type: EXPERIMENTAL
Intervention: Total IgG levels in MI subjects with MACE (24.9 mg/mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Total IgG levels in controls (18.4 mg/mL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Quartiles 3 and 4 of total IgG in MI subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels in MI subjects with MACE (1.1 mg/mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: C-reactive protein (CRP) levels in controls (1.9 mg/mL)
Number of subjects: 40
Study: 30081016

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (CEE 0.625 mg/day)
Number of subjects: 8102

Group type: EXPERIMENTAL
Intervention: Oral CEE + medroxyprogesterone acetate (CEE 0.625 mg/day + MPA 2.5 mg/day)
Number of subjects: 8102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8102